Shares of Teladoc, Inc. (NYSE:TDOC) have been given a consensus recommendation of “Buy” by the fifteen ratings firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $39.09.

TDOC has been the subject of several recent analyst reports. Cowen Inc restated an “outperform” rating and set a $39.00 price objective (up previously from $36.00) on shares of Teladoc in a research report on Thursday, August 3rd. Oppenheimer Holdings, Inc. boosted their price objective on shares of Teladoc from $40.00 to $45.00 and gave the stock an “outperform” rating in a research report on Tuesday. Canaccord Genuity set a $42.00 price objective on shares of Teladoc and gave the stock a “buy” rating in a research report on Friday, November 17th. SunTrust Banks, Inc. restated a “buy” rating and set a $40.00 price objective on shares of Teladoc in a research report on Friday, November 3rd. Finally, BidaskClub downgraded shares of Teladoc from a “hold” rating to a “sell” rating in a research report on Thursday, August 3rd.

In related news, CEO Jason N. Gorevic sold 20,000 shares of the company’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $32.10, for a total value of $642,000.00. Following the completion of the sale, the chief executive officer now owns 838,261 shares in the company, valued at approximately $26,908,178.10. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Mark Hirschhorn sold 10,000 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $34.04, for a total transaction of $340,400.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 135,000 shares of company stock valued at $4,408,700. 4.47% of the stock is owned by insiders.

Hedge funds have recently added to or reduced their stakes in the stock. ETF Managers Group LLC purchased a new stake in Teladoc in the 2nd quarter valued at $104,000. Bank of Montreal Can raised its position in Teladoc by 214.2% in the 2nd quarter. Bank of Montreal Can now owns 3,516 shares of the health services provider’s stock valued at $123,000 after purchasing an additional 2,397 shares during the last quarter. Pacad Investment Ltd. purchased a new stake in Teladoc in the 2nd quarter valued at $135,000. Fred Alger Management Inc. purchased a new stake in Teladoc in the 2nd quarter valued at $139,000. Finally, Ameritas Investment Partners Inc. raised its position in Teladoc by 134.2% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,724 shares of the health services provider’s stock valued at $164,000 after purchasing an additional 2,707 shares during the last quarter.

Shares of Teladoc (NYSE TDOC) traded up $1.25 during trading hours on Monday, hitting $35.25. 833,891 shares of the stock traded hands, compared to its average volume of 1,089,488. The company has a quick ratio of 5.08, a current ratio of 5.08 and a debt-to-equity ratio of 0.83. Teladoc has a twelve month low of $15.65 and a twelve month high of $37.55.

Teladoc (NYSE:TDOC) last issued its quarterly earnings data on Wednesday, November 1st. The health services provider reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.25). The company had revenue of $68.70 million for the quarter, compared to analysts’ expectations of $67.53 million. Teladoc had a negative return on equity of 21.59% and a negative net margin of 39.61%. The firm’s quarterly revenue was up 112.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.33) EPS. equities research analysts forecast that Teladoc will post -1.57 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This story was first reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another website, it was illegally copied and reposted in violation of international trademark and copyright legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/teladoc-inc-tdoc-receives-38-18-average-target-price-from-analysts/1726516.html.

Teladoc Company Profile

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Analyst Recommendations for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.